Načítá se...
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
LESSONS LEARNED. Clofarabine can be active in relapsed and refractory lymphoid malignancies on a weekly dosing schedule. Responses were seen in patients with T‐cell lymphomas, including cutaneous T‐cell lymphoma, but not in patients with aggressive B‐cell lymphomas. BACKGROUND. Clofarabine is a seco...
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5896711/ https://ncbi.nlm.nih.gov/pubmed/29438091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0658 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|